Synthesis and Characterization of Process-Related Impurities of Antidiabetic Drug Linagliptin

Synthesis and Characterization of Process-Related Impurities of Antidiabetic Drug Linagliptin

Linagliptin, a xanthine derivative, is a highly potent, selective, long-acting and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. During the process development of linagliptin, five new process-related impurities were detected by high performance liquid chromatography (HPL...

Full description

Bibliographic Details
Main Authors:	Yiwen Huang, Xiaoqing He, Taizhi Wu, Fuli Zhang
Format:	Article
Language:	English
Published:	MDPI AG 2016-08-01
Series:	Molecules
Subjects:	linagliptin type 2 diabetes impurities synthesis characterization
Online Access:	http://www.mdpi.com/1420-3049/21/8/1041

Similar Items

Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post‐marketing surveillance study in Japan
by: Soulmaz Fazeli Farsani, et al.
Published: (2019-09-01)

Renal insufficiency and linagliptin therapy: a case report
by: Anna Corsi, et al.
Published: (2018-09-01)

Journey from EMPA-REG to CARMELINA to EMPEROR-Preserved: Empagliflozin/linagliptin in heart failure and diabetes
by: Sharvil S Gadve, et al.
Published: (2022-01-01)

HPLC-DAD technique for the quantification of a recently approved anti-diabetic triple combination along with two toxic official impurities: Toxicity confirmation aided by molecular docking application
by: Eman A. Bahgat, et al.
Published: (2023-03-01)

Identification, synthesis, and characterization of potential genotoxic impurities of sildenafil citrate drug substance
by: P. Rajesh Reddy, et al.
Published: (2020-11-01)

Palpable Purpura in a Patient with Uncontrolled Type 2 Diabetes Mellitus: Possible Side Effect of Linagliptin
by: Ömercan Topaloğlu, et al.
Published: (2019-03-01)

Linagliptin in the frail elderly diabetic patient
by: Eva Palmieri
Published: (2018-09-01)

Comparison of effects of Empagliflozin and Linagliptin on renal function and glycaemic control: a double-blind, randomized clinical trial
by: Mohammad Amin Mohammad zadeh Gharabaghi, et al.
Published: (2022-05-01)

A new challenge for linagliptin: diabetes, organ transplantation and chronic renal insufficiency in the same patient
by: Benedetta M. Bonora
Published: (2018-09-01)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012-06-01)

Post-marketing Study of Linagliptin: A Pilot Study
by: Gabrielle Kéfrem Alves Gomes, et al.
Published: (2019-05-01)

Green quantitative methods for linagliptin and empagliflozin in dosage forms
by: Fraihat Safwan M.
Published: (2024-04-01)

Comparison of the efficacy of dapagliflozin and linagliptin in the treatment of type 2 diabetes patients with normal body mass index and poor metformin monotherapy
by: Mingli He, et al.
Published: (2024-01-01)

A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers
by: Kang WY, et al.
Published: (2020-05-01)

A Localized Painful Rash Induced by Linagliptin in a Patient with type 2 Diabetes
by: İsmail Yıldız, et al.
Published: (2019-05-01)

CHARACTERIZATION OF LINAGLIPTIN USING ANALYTICAL TECHNIQUES
by: Amanda Thomas Barden, et al.
Published: (2017-12-01)

Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin
by: Farr AM, et al.
Published: (2016-08-01)

A Comparison of Renal Effects between Empagliflozin and Linagliptin in Diabetic Patients with Chronic Kidney Disease: A Randomized Clinical Trial
by: Reza Zeinabadi Noghabi, et al.
Published: (2024-06-01)

Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus
by: Feng Tian, et al.
Published: (2023-02-01)

DSC, FT-IR and NIR with Chemometric Assessment Using PCA and HCA for Estimation of the Chemical Stability of Oral Antidiabetic Drug Linagliptin in the Presence of Pharmaceutical Excipients
by: Anna Gumieniczek, et al.
Published: (2022-07-01)

Solriamfetol impurities: Synthesis, characterization, and analytical method (UPLC-UV) validation
by: Nafisah Al-Rifai, et al.
Published: (2023-04-01)

Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series
by: Manash P Baruah, et al.
Published: (2016-01-01)

A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting
by: Debmalya Sanyal, et al.
Published: (2013-01-01)

Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial
by: Hassan B. Awal, et al.
Published: (2020-06-01)

Development of RP-HPLC, Stability Indicating Method for Degradation Products of Linagliptin in Presence of Metformin HCl by Applying 2 Level Factorial Design; and Identification of Impurity-VII, VIII and IX and Synthesis of Impurity-VII
by: Sushant B. Jadhav, et al.
Published: (2017-06-01)

A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19
by: Ran Abuhasira, et al.
Published: (2021-12-01)

Linagliptin ameliorated cardiac fibrosis and restored cardiomyocyte structure in diabetic mice associated with the suppression of necroptosis
by: Juthi Adhikari, et al.
Published: (2023-07-01)

Clinical efficacy and safety of linagliptin in patients with diabetes type 2
by: E. V. Biryukova, et al.
Published: (2016-12-01)

An efficient synthesis of 2-(4-(benzyloxy)phenyl)-N, N-dimethylacetamide substantially free from impurities – Synthesis & characterization of novel impurities
by: Sachin Sonavane, et al.
Published: (2021-01-01)

Analytical Enantio-Separation of Linagliptin in Linagliptin and Metformin HCl Dosage Forms by Applying Two-Level Factorial Design
by: Sushant B. Jadhav, et al.
Published: (2016-10-01)

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
by: Johansen Odd, et al.
Published: (2012-01-01)

Plasma Nitrate Levels Are Related to Metabolic Syndrome and Are Not Altered by Treatment with DPP-4 Inhibitor Linagliptin: A Randomised, Placebo-Controlled Trial in Patients with Early Type 2 Diabetes Mellitus
by: Melanie Reijrink, et al.
Published: (2021-09-01)

Linagliptin Regulates the Mitochondrial Respiratory Reserve to Alter Platelet Activation and Arterial Thrombosis
by: Yi Li, et al.
Published: (2020-11-01)

Multi-Gram Scale Synthesis and Characterization of Mometasone Furoate EP Impurity C
by: Riccardo Ronchetti, et al.
Published: (2023-11-01)

Neuroprotective Impact of Linagliptin against Cadmium-Induced Cognitive Impairment and Neuropathological Aberrations: Targeting SIRT1/Nrf2 Axis, Apoptosis, and Autophagy
by: Hany H. Arab, et al.
Published: (2023-07-01)

Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction
by: M. A. Cherepanova
Published: (2018-02-01)

A careful evaluation of the therapeutic choice is necessary in every phase of diabetes progression
by: Maria Elena Malighetti
Published: (2018-09-01)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
by: Han E, et al.
Published: (2020-11-01)

Linagliptin is associated to increased treatment adherence and satisfaction in elderly outpatients with diabetes and advanced chronic kidney disease
by: Franco Gregorio, et al.
Published: (2016-11-01)

Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans
by: Jin-Woo Park, et al.
Published: (2022-03-01)